Reviewing Syneos Health (SYNH) and US Stem Cell (USRM)

Syneos Health (NASDAQ:SYNH) and US Stem Cell (OTCMKTS:USRM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Syneos Health and US Stem Cell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syneos Health -4.32% 7.80% 3.17%
US Stem Cell -30.23% N/A -99.85%



Earnings & Valuation

This table compares Syneos Health and US Stem Cell’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syneos Health $2.67 billion 1.76 -$138.46 million $1.94 23.52
US Stem Cell $5.52 million 1.83 -$3.48 million N/A N/A

US Stem Cell has lower revenue, but higher earnings than Syneos Health.

Risk and Volatility

Syneos Health has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 6.57, meaning that its stock price is 557% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Syneos Health and US Stem Cell, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syneos Health 0 2 10 0 2.83
US Stem Cell 0 0 0 0 N/A

Syneos Health presently has a consensus price target of $54.60, suggesting a potential upside of 19.66%. Given Syneos Health’s higher possible upside, analysts clearly believe Syneos Health is more favorable than US Stem Cell.

Summary

Syneos Health beats US Stem Cell on 6 of the 9 factors compared between the two stocks.

About Syneos Health

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply